Twenty-six eyes of 24 patients with advanced glaucoma refractory to conventional therapy were treated with noncontact neodymium:YAG laser cyclophotocoagulation and were followed for a minimum of 6 months postoperatively. The mean baseline intraocular pressure (IOP) was 34.2 ± 2.0 mm Hg. Nine to 10 evenly spaced pulses per quadrant were circumferentially applied 2.0–2.5 mm posterior to the limbus. Eight to 35 pulses (mean, 19 pulses) were delivered per treatment with an energy per pulse of 3.9–5.7 J (mean, 4.7 J), and the total energy per treatment was 35.6–164.9 J (mean, 91.1 J). Twelve eyes of 11 patients (46%) required 2 or more treatments (mean, 1.7). The mean final IOP was 17.0 ± 2.1 mm Hg, and the mean percent decrease in IOP was 41.7 ± 6.5%. Statistical analyses revealed that the IOP reached its lowest point about 1 week after treatment and remained at that level through 6 months of follow-up. There were significant correlations between the percent pressure decrease and preoperative IOP, the number of administered pulses and the total energy at the last procedure. Based on these results, we introduce intentional multiple treatments as a new manner of treatment to avoid phthisis bulbi. An initial treatment is performed circumferentially for 180°, and if sufficient pressure reduction is not obtained, an additional treatment for 180° should be employed 1 week after the most recent procedure, whether initial or not.

Keywords:
Cyclophotocoagulation, Uncontrolled glaucoma, Nd: YAG laser, Pressure-lowering effect
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.